Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;35(5):e15366.
doi: 10.1111/dth.15366. Epub 2022 Feb 18.

Impact of extracorporeal photopheresis on blood and coagulation parameters

Affiliations

Impact of extracorporeal photopheresis on blood and coagulation parameters

Thilo Gambichler et al. Dermatol Ther. 2022 May.

Abstract

Extracorporeal photopheresis (ECP) is considered a safe treatment modality. We aimed to assess blood parameters including coagulation during ECP over time. We performed a long-term retrospective single-center chart review (laboratory parameters) of adult patients (n = 172) who had received ECP for any indication. We observed a significant decrease (p < 0.05) in erythrocytes, hemoglobin, and leukocytes compared to baseline levels after only one ECP procedure. This decrease persisted after 3-, 6-, 9-, and 12-months of ECP. A significant pathological decline of hemoglobin was observed in a higher proportion (26.4% and 25.2%, respectively) of patients after 6 (p = 0.0007) and 12 (p = 0.012) months of ECP. Mean corpuscular volume as well as hematocrit was significantly decreased at 3-, 6-, 9-, and 12-months of evaluation compared to baseline (p < 0.05). After 9 and 12 months of ECP we observed a further decline in lymphocyte counts (p < 0.05). Various coagulation parameters did not change significantly during ECP treatment. Even though not all alterations observed in peripheral blood of ECP patients in the present study were of clinical significance, risk for developing persistent anemia must be considered in patients undergoing ECP.

Keywords: blood parameters; coagulation; extracorporeal photopheresis.

PubMed Disclaimer

References

REFERENCES

    1. McPherson RA, Buckler AG, Sanford KW, Roseff SD. Investigation of heparin-related hypotensive adverse events during photopheresis: utility of a patient care database. Transfusion. 2011;51(6):1314-1320.
    1. Edelson RL. Extracorporeal photopheresis. Photodermatol. 1984;1(5):209-210.
    1. Knobler R, Arenberger P, Arun A, et al. European dermatology forum-updated guidelines on the use of extracorporeal photopheresis 2020-part 1. J Eur Acad Dermatol Venereol. 2020;34(12):2693-2716.
    1. Knobler R, Arenberger P, Arun A, et al. European dermatology forum: updated guidelines on the use of extracorporeal photopheresis 2020-part 2. J Eur Acad Dermatol Venereol. 2021;35(1):27-49.
    1. Vieyra-Garcia PA, Wolf P. Extracorporeal photopheresis: a case of immunotherapy ahead of its time. Transfus Med Hemother. 2020;47(3):226-235.

LinkOut - more resources